Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24572629 | 0.85 | LMNA (0.63) | LMNASMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL20224802 | 0.85 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL31720364 | 0.84 | HTT (0.57) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL20188195 | 0.84 | HTT (0.53) | LMNASMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL2242018 | 0.83 | SMN1; SMN2 (0.72) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL31749309 | 0.82 | LMNA (0.48) | LMNASMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL30290791 | 0.81 | LMNA (0.49) | LMNASMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL17841845 | 0.81 | LMNA (0.68) | LMNASMN1; SMN2HTTALDH1A1L3MBTL1 | |
| SCHEMBL24572574 | 0.80 | LMNA (0.56) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL21069619 | 0.80 | SMN1; SMN2 (0.85) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250388614-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4658263-A2 | COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS | Yale University (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250161460-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2025-05-22 | — | — | US | disclosed |
| US-12234256-B2 | Molecular degraders of extracellular proteins | YALE UNIVERSITY (US) | 2025-02-25 | — | — | US | disclosed |
| US-12128105-B2 | Molecular degraders of extracellular proteins | YALE UNIVERSITY (US) | 2024-10-29 | — | — | US | disclosed |
| WO-2024163610-A2 | COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS | YALE UNIVERSITY (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-4392430-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | Yale University (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-117897177-A | Molecular degradation agent for extracellular proteins | 耶鲁大学 | 2024-04-16 | — | — | CN | disclosed |
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2023028590-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | LMNA 2180/4885SMN1; SMN2 3100/4885HTT 4263/4885 |
| US-20260125410-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, FCGR2A | LMNA 1409/4885SMN1; SMN2 4099/4885HTT 4404/4885 |
| US-20250161460-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | LMNA 2180/4885SMN1; SMN2 3100/4885HTT 4263/4885 |
| US-12128105-B2 | Molecular degraders of extracellular proteins | ASGR1, MSR1, LDLR | LMNA 2180/4885SMN1; SMN2 3100/4885HTT 4263/4885 |
| US-20250388614-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, COL2A1, LDLR | LMNA 1275/4885SMN1; SMN2 3414/4885HTT 4019/4885 |
| US-12234256-B2 | Molecular degraders of extracellular proteins | ASGR1, MSR1, LDLR | LMNA 2180/4885SMN1; SMN2 3100/4885HTT 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.